Sinobest Biotech

Sinobest Biotech is a clinical-stage biopharmaceutical company headquartered in Beijing, China, focused on the development of innovative small molecule drugs. The company primarily targets metabolic diseases, autoimmune disorders, and oncology, with a specific emphasis on high-prevalence conditions like gout and hyperuricemia. Its lead program, Sino-101, is a highly selective URAT1 inhibitor designed to provide superior efficacy and safety for patients with chronic gout. Additionally, Sinobest is advancing a pipeline of targeted therapies, including JAK1 inhibitors for inflammatory diseases and FGFR inhibitors for cancer treatment. The company leverages its internal research and development capabilities to identify and optimize candidates with best-in-class potential.